Search research articles
Contact Us
Filters
Showing results (321-330 of 345) with videos related to
Page
of 35
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 15, 2025
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
Romain Aymon, Denis Mongin, Romain Guemara, et al.
Annals of the Rheumatic Diseases
|
January 6, 2018
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis
Helga Radner, Katerina Chatzidionysiou, Elena Nikiphorou, et al.
Rheumatology (Oxford, England)
|
November 30, 2014
The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers
Lianne Kearsley-Fleet, Jakub Závada, Merete Lund Hetland, et al.
Annals of the Rheumatic Diseases
|
December 31, 2024
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Eden Sebbag, Kim Lauper, Juan Molina-Collada, et al.
Arthritis Care & Research
|
June 26, 2024
Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries
Louise Linde, Stylianos Georgiadis, Lykke M Ørnbjerg, et al.
Annals of the Rheumatic Diseases
|
February 1, 2025
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases
|
December 31, 2024
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases
|
June 4, 2021
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
Ulf Lindström, Daniela Di Giuseppe, Bénédicte Delcoigne, et al.
Rheumatology (Oxford, England)
|
March 24, 2022
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis
Michael Nissen, Bénédicte Delcoigne, Daniela Di Giuseppe, et al.
Annals of the Rheumatic Diseases
|
March 4, 2025
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Peter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Page
of 35
Search research articles
Search
Showing results (321-330 of 345) with videos related to
Sort By:
Page
of 35
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 15, 2025
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
Romain Aymon, Denis Mongin, Romain Guemara, et al.
Annals of the Rheumatic Diseases
|
January 6, 2018
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis
Helga Radner, Katerina Chatzidionysiou, Elena Nikiphorou, et al.
Rheumatology (Oxford, England)
|
November 30, 2014
The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers
Lianne Kearsley-Fleet, Jakub Závada, Merete Lund Hetland, et al.
Annals of the Rheumatic Diseases
|
December 31, 2024
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Eden Sebbag, Kim Lauper, Juan Molina-Collada, et al.
Arthritis Care & Research
|
June 26, 2024
Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries
Louise Linde, Stylianos Georgiadis, Lykke M Ørnbjerg, et al.
Annals of the Rheumatic Diseases
|
February 1, 2025
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases
|
December 31, 2024
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer
Eden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases
|
June 4, 2021
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
Ulf Lindström, Daniela Di Giuseppe, Bénédicte Delcoigne, et al.
Rheumatology (Oxford, England)
|
March 24, 2022
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis
Michael Nissen, Bénédicte Delcoigne, Daniela Di Giuseppe, et al.
Annals of the Rheumatic Diseases
|
March 4, 2025
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Peter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Page
of 35